Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cytogenetics molecular
Show results for
Products
Services
Software

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Cytogenetics Molecular Articles & Analysis

8 news found

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

” “MDS patients typically have multiple molecular aberrations which impact how they respond to treatment,” said Dr. ...

ByCellworks Research India Private Limited


Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients

Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients

The platform is powered by the groundbreaking Cellworks Computational Biology Model (CBM), a highly curated mechanistic network of 6,000+ human genes, 30,000 molecular species and 600,000+ molecular interactions. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and ...

ByCellworks Research India Private Limited


Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award

Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award

The platform is powered by Cellworks groundbreaking Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks ...

ByCellworks Research India Private Limited


Cellworks Singula TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

Cellworks Singula TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

The platform is powered by Cellworks groundbreaking Computational Omics Biology Model (CBM), a network of 7,000+ human genes, 30,000+ molecular species and 100+ signaling pathways. As part of the biosimulation process, personalized disease models are created for each patient using their cytogenetic and molecular data as input to the Cellworks ...

ByCellworks Research India Private Limited


Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

“Using Cellworks SingulaTM TRI, we can simulate the molecular effects of cell signaling, drugs and radiation on patient-specific in silico diseased cells prior to treatment and then identify the magnitude of disease control and survival for specific anti-tumor strategies. ...

ByCellworks Research India Private Limited


Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

Cellworks Singula TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

” “Gaining a better understanding of the molecular determinants of gastroesophageal adenocarcinoma is key to improving therapy response rates for GEA patients,” Dr. ...

ByCellworks Research India Private Limited


myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

The myCare-023 study also showed that the Cellworks platform can provide personalized, molecular-based alternate treatment options for AML patients who are predicted to be non-responders to standard care therapies. ...

ByCellworks Research India Private Limited


Metaglut1, A New Diagnostic Test for the Glut1 Deficiency Syndrome

Metaglut1, A New Diagnostic Test for the Glut1 Deficiency Syndrome

With a state-of-the-art technological platform, it is able to offer private and hospital laboratories in over 50 countries a wide range of specialised biological tests in fields such as molecular biology, oncology, allergology, toxicology, hormonology, and infectious and metabolic diseases together with diagnostic analyses for genetic diseases in cytogenetics and ...

ByMetafora Biosystems

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT